LONDON (Reuters) - Uncertainty over European exclusivity for Sanofi's new multiple sclerosis (MS) pill Aubagio could disrupt the wider market and impact other companies, according to a leading industry analyst. The French drugmaker won an approval recommendation on Friday for the medicine from the European Medicines Agency, but the regulator refused to give it a "new active substance" (NAS) designation because it is very similar to a much older drug. ... via Health News Headlines - Yahoo! News Read More Here..
No comments:
Post a Comment